Skip to main content

Research Repository

Advanced Search

Outputs (13)

Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma (2024)
Journal Article
Bishton, M. J., Crooks, C. J., Card, T. R., & West, J. (2024). Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma. British Journal of Haematology, 204(6), 2222-2226. https://doi.org/10.1111/bjh.19371

To address the lack of contemporary population-based epidemiological studies of hepatosplenic T-cell lymphoma (HSTCL), we undertook a population-based study of ICD-O-3-coded HSTCL in England. We used the National Cancer Registration Dataset and linke... Read More about Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma.

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article
Shotton, R., Broadbent, R., Alchawaf, A., Mohamed, M. B., Gibb, A., Martinez-Calle, N., Fox, C. P., Bishton, M., Pender, A., Gleeson, M., Cunningham, D., Davies, A. J., Yadollahi, S., Eyre, T. A., Collins, G. P., Djebbari, F., Kassam, S., Garland, P., Watts, E., Osborne, W., …Linton, K. M. (2024). Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Blood Advances, 8(4), 878-888. https://doi.org/10.1182/bloodadvances.2023011305

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non- Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline (2023)
Journal Article
Eyre, T. A., Bishton, M. J., McCulloch, R., O'Reilly, M., Menon, G., Iyengar, S., Lewis, D., Lambert, J., Linton, K. M., McKay, P., & Haemato-Oncology Task Force of the British Society for Haematology, H.-O. T. F. O. T. B. S. F. H. (2024). Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline. British Journal of Haematology, 204(1), 108-126. https://doi.org/10.1111/bjh.19131

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article
Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., Cwynarski, K., Bishton, M. J., Fox, C. P., Hawkes, E. A., Maurer, M. J., El-Galaly, T. C., Cheah, C. Y., Bobillo, S., Caporn, P. L., Van Zyl, J., Klanova, M., Trněny, M., Puckrin, R., Stewart, D. A., …Pophali, P. A. (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Journal of Clinical Oncology, 41(35), 5376-5387. https://doi.org/10.1200/JCO.23.00365

PURPOSE
CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexat... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018 (2023)
Journal Article
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T., Lanyon, P., Nanduri, V., Rankin, J., Bishton, M., & Crooks, C. (2023). 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018. Journal of Hematology and Oncology, 16, Article 56. https://doi.org/10.1186/s13045-023-01434-4

Haemophagocytic lymphohistiocytosis (HLH) is a lethal syndrome of excessive immune activation. We undertook a nationwide study in England of all cases of HLH diagnosed between 2003 and 2018, using linked electronic health data from hospital admission... Read More about 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018.

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (2022)
Journal Article
Nastoupil, L., Morschhauser, F., Scholz, C. W., Bishton, M., Yoon, S.-S., Giri, P., wei, M. C., Knapp, A., Li, C. C., Bottos, A., Li, H., Purev, E., & Bartlett, N. L. (2022). P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere, 6(S3), 1015-1016. https://doi.org/10.1097/01.HS9.0000847368.92731.fb

Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data (2021)
Journal Article
Halligan, S. J., Grainge, M. J., Martinez-Calle, N., Fox, C. P., & Bishton, M. J. (2022). Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data. British Journal of Haematology, 196(4), 932-938. https://doi.org/10.1111/bjh.17896

Systemic anaplastic large cell lymphoma (sALCL) is a rare T-cell lymphoma associated with poor prognosis after relapse. The immuno-conjugate Brentuximab Vedotin (BV) first became available for relapsed sALCL in England in 2013, following the results... Read More about Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data.

Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom (2021)
Journal Article
Kaji, F. A., Martinez‐Calle, N., Bishton, M. J., Figueroa, R., Adlington, J., O’Donoghue, M., Smith, S., Byrne, P., Paine, S., Sovani, V., Auer, D., James, E., Bessell, E. M., Grainge, M. J., & Fox, C. P. (2021). Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. British Journal of Haematology, 195(4), 561-570. https://doi.org/10.1111/bjh.17747

Observational studies with long-term follow-up of patients with primary central nervous system lymphoma (PCNSL) are scarce. Patient data over a period of four decades were retrospectively analysed from databases at Not-tingham University Hospitals Tr... Read More about Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.